Search the Newsreel

Pluri Inc. FY 2026: Revenue $1.02M, EPS $(2.44) — 10-K Summary

Pluri Inc. reported its fiscal 2026 financial results, showing a net loss of $23.82 million on revenues of $1.02 million, a 24% decrease year-over-year. Despite the widened net loss, diluted EPS improved to $(2.44) due to a higher share count. The company attributed the …

Pluri: Fiscal Q4 Earnings Snapshot

Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2026

Pluri Inc. (NASDAQ: PLUR) Share Price, PLUR Stock News, PLUR Share Price & Updates

Pluri Inc. (NASDAQ: PLUR) is a biotechnology company focused on developing placenta-based cell therapy products for inflammatory, muscle, and hematologic conditions. The company's pipeline includes PLX-PAD and PLX-R18, both derived from placental cells, undergoing various clinical study phases. Despite limited public disclosure and a …

Pluri (PLUR) turns to private warrants for funding

Pluri Inc. (PLUR) has reported a $3.68 million Rule 506(b) exempt private offering of warrants, which has been fully allocated. This offering is distinct from a concurrent registered direct offering. The first sale in this warrant offering was on August 28, 2026, and no …

Pluri Inc. (PLUR) Peer Comparison – Compare with Others

Pluri Announces August 2026 Equity Financing Transaction

Pluri Inc. has completed an equity financing transaction in August 2026, raising approximately $2.98 million through a direct offering of common shares and pre-funded warrants to an institutional investor, alongside a private placement of common warrants. This move aims to bolster liquidity and fund …

Pluri Inc. (PLUR) Edges Higher Above $1.46 Support as Consolidation Continues - Tick Index

Pluri (NASDAQ: PLUR) raises cash as funding falls under three months

Pluri Inc. (PLUR) Edges Higher Above $1.46 Support as Consolidation Continues - Wyckoff Accumulation

Pluri raises $3.3 million in registered direct offering

Pluri Inc. has announced a registered direct offering to a healthcare-focused institutional investor, generating approximately $3.3 million in gross proceeds from the sale of 2,228,940 common shares at $1.50 each. Concurrently, the biotechnology company will issue warrants for an additional 2,228,940 common shares at …

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Earnings Flash (PLUR.V) Plurilock Security Inc. Reports Q2 Revenue C$11.3M

Pluri (PLUR) director's 31,569-share grant vests over 3 years

Pluri Inc. (PLUR) director Doron Shorrer was granted 31,569 Restricted Stock Units (RSUs) on August 20, 2026, which will vest over a three-year period. Following this grant, Shorrer directly holds 38,228 common shares and indirectly holds 6,969 common shares through Shorrer International Ltd. The …

Pluri Inc. (PLUR) insider logs stock trades in new SEC filing

Pluri Inc. (PLUR) director and 10% owner Manieu Alexandre Weinstein has filed a Form 4 with the SEC, indicating the grant of 180,000 common shares underlying restricted stock units (RSUs) on August 20, 2026. These RSUs will vest over three years. Following this transaction, …

Pluri (PLUR) Results at a Glance: The EPS Result Is Below Expectation; Trading Response: Shares Finish 0.57% Up - Quarterly Earnings Report

Pluri (PLUR) Results at a Glance: The EPS Result Is Below Expectation; Trading Response: Shares Finish 0.57% Up - Earnings Sentiment Score

Pluri (PLUR) Results at a Glance: The EPS Result Is Below Expectation; Trading Response: Shares Finish 0.57% Up - Earnings Surprise Score

Pluri Subsidiary to Acquire Fishway BV, Diluting Pluri Stake to 58%

Pluri Inc.'s majority-owned subsidiary, Ever After Foods Ltd. (EAF), is set to acquire Fishway BV in an all-stock deal, aiming to strengthen EAF's European strategy in cultivated seafood. While this acquisition will bolster EAF's research capabilities and is supported by a $2.0 million SAFE …

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri's majority-owned food-tech company, Ever After Foods (EAF), has acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free media development. This acquisition enhances EAF's cultivated-protein platform and expands its European scientific presence. Concurrently, EAF secured an additional $2 million …

Pluri Inc. (PLUR) Holds at $1.75 as Traders Eye Key Support and Resistance - Bull Pennant

PLUR Q2 2026 Earnings: Wider-Than-Expected Loss Reflects Continued Investment in Cell Therapy Pipeline - Long-Term Guidance

Pluri Inc (PLUR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Pluri Inc. Revenue Breakdown – NASDAQ:PLUR

Pluri Inc (PLUR) Stock News Today

This article provides a brief update on Pluri Inc (PLUR) stock news, indicating that more news is expected soon. It also lists key financial data for Pluri Inc, including its stock price, market cap, and P/E TTM. The article appears to be a placeholder …

PLUR Q2 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Investment - Gross Profit Margin

PLUR Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Investment - Revenue Guidance Update

Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pluri Inc (PLUR), highlighting its current price momentum score of 4.86 and its position between resistance at $1.92 and support at $1.32, suggesting suitability for range-bound swing trading. It details various technical indicators like MACD, RSI, and …

Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pluri Inc (PLUR), highlighting its current risk score of 2.15, which ranks 234 out of 384 in the Biotechnology & Medical Research industry. It details the company's beta value of 0.66, indicating underperformance in rising markets and …

Pluri Inc. Revenue Breakdown – FWB:4DX

This article provides a revenue breakdown for Pluri Inc. (FWB:4DX), highlighting that the largest contribution to its revenue came from Israel, generating 1.13 million EUR last year and 304.35K EUR the year prior. The information is presented within the financial overview section of TradingView.

PLUR Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Investment Costs - Management Guidance Update

Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis

Pluri Inc (PLUR) has a weak financial status and low operating efficiency, ranking 368 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.27. The company's latest quarterly revenue decreased by 60.89% year-over-year, and its net profit saw …

Pluri subsidiary completes UK regulatory registration for aesthetics product By Investing.com

Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has secured regulatory registration in the UK for its regenerative aesthetics product, Regenativo+. This registration allows commercial marketing of Regenativo+ in the UK market, estimated at $900 million in 2026, and follows previous regulatory progress in …